Christophe Hibos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Christophe Hibos has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- François Ghiringhelli
Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France
8 shared publications - Frédérique Végran
Université Bourgogne Europe, Centre de Lutte Contre Le Cancer G-F. Leclerc, INSERM, CTM UMR 1231 [Equipe TIRECS], Dijon, France
7 shared publications - Lionel Apetoh
Department of Microbiology & Immunology, Indiana University School of Medicine, Indianapolis, IN, United States; Brown Center for Immunotherapy, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United States
7 shared publications - Caroline Truntzer
Université Bourgogne Europe, Centre Georges-François Leclerc, Unicancer, Cancer Biology Transfer Platform, INSERM, CTM UMR 1231, TIRECs team
6 shared publications - Mélanie Bruchard
Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, 21000 Dijon, France
6 shared publications - Romain Boidot
Centre Georges-François Leclerc, Université Bourgogne Europe, Unicancer, Molecular Biology Unit, Dijon, France
6 shared publications
Latest Publications
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Étude des fonctions indépendantes de l’inflammasome de NLRP3 dans les lymphocytes T et de leurs impacts sur la réponse immunitaire antitumorale
Dans la grande majorité des cancers, les lymphocytes T CD8 infiltrant la tumeur sont associés à un meilleur pronostic. Le rôle des T CD4 est, quant à lui, plus contrasté. Au cours du temps, la réponse antitumorale des lymphocytes T s'affaiblit. Les thérapies de blocage des points de contrôle immunitaires à base d'anticorps monoclonaux permettent de restaurer la fonction antitumorale des lymphocytes T. Bien que l'efficacité des thérapies de blocage des points de contrôle varie selon le type de cancer, le taux de réponse a rarement dépassé 20%. Ainsi, un défi majeur dans le domaine de l'immunothérapie consiste à comprendre les mécanismes moléculaires de la réponse immunitaire antitumorale afin de généraliser la réponse aux traitements.La protéine NLRP3 est un membre de la famille des récepteurs Nod-like (NLR). Dans les cellules myéloïdes, la protéine cytoplasmique NLRP3 forme un complexe appelé inflammasome. Dans le cas des cellules lymphoïdes, il a été observé que la protéine NLRP3 possède des fonctions indépendantes de l’inflammasome et module la différenciation des cellules T CD4 Th2. Ce travail de recherche est basé sur des données préliminaires montrant que la déficience en NLRP3 affecte l’activation des cellules CD4 Th17 et T CD8.Durant ma thèse, et pour explorer les fonctions NLRP3 dans les cellules T CD4 et T CD8 dans un contexte de cancer, nous avons caractérisé les cellules T CD4 et T CD8 déficientes pour NLRP3 dans un modèle de souris transgéniques. Ensuite, nous avons évalué si la fonction dépendante ou indépendante de l'inflammasome NLRP3 sont impliquées dans la biologie des T CD8. Nous avons ensuite caractérisé l'impact du déficit en NLRP3 sur les fonctions antitumorales des T CD8 ainsi que l'impact du niveau d'expression de NLRP3 sur la réponse aux traitements. Enfin, nous avons mis en lumière la voie de signalisation associée aux effets immunosuppresseurs de NLRP3 dans les T CD4 et les T CD8.De telles découvertes fondamentales pourraient être utilisées pour développer des outils ciblant les cellules T. Grâce à mes travaux, nous pensons que NLRP3 régule l'activation et/ou la différenciation des lymphocytes T CD4 et des T CD8 chez la souris, permettant l'identification de nouvelles cibles thérapeutiques pour éviter ou inverser l'immunosuppression associée à NLRP3.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Étude des fonctions indépendantes de l’inflammasome de NLRP3 dans les lymphocytes T et de leurs impacts sur la réponse immunitaire antitumorale
Dans la grande majorité des cancers, les lymphocytes T CD8 infiltrant la tumeur sont associés à un meilleur pronostic. Le rôle des T CD4 est, quant à lui, plus contrasté. Au cours du temps, la réponse antitumorale des lymphocytes T s'affaiblit. Les thérapies de blocage des points de contrôle immunitaires à base d'anticorps monoclonaux permettent de restaurer la fonction antitumorale des lymphocytes T. Bien que l'efficacité des thérapies de blocage des points de contrôle varie selon le type de cancer, le taux de réponse a rarement dépassé 20%. Ainsi, un défi majeur dans le domaine de l'immunothérapie consiste à comprendre les mécanismes moléculaires de la réponse immunitaire antitumorale afin de généraliser la réponse aux traitements.La protéine NLRP3 est un membre de la famille des récepteurs Nod-like (NLR). Dans les cellules myéloïdes, la protéine cytoplasmique NLRP3 forme un complexe appelé inflammasome. Dans le cas des cellules lymphoïdes, il a été observé que la protéine NLRP3 possède des fonctions indépendantes de l’inflammasome et module la différenciation des cellules T CD4 Th2. Ce travail de recherche est basé sur des données préliminaires montrant que la déficience en NLRP3 affecte l’activation des cellules CD4 Th17 et T CD8.Durant ma thèse, et pour explorer les fonctions NLRP3 dans les cellules T CD4 et T CD8 dans un contexte de cancer, nous avons caractérisé les cellules T CD4 et T CD8 déficientes pour NLRP3 dans un modèle de souris transgéniques. Ensuite, nous avons évalué si la fonction dépendante ou indépendante de l'inflammasome NLRP3 sont impliquées dans la biologie des T CD8. Nous avons ensuite caractérisé l'impact du déficit en NLRP3 sur les fonctions antitumorales des T CD8 ainsi que l'impact du niveau d'expression de NLRP3 sur la réponse aux traitements. Enfin, nous avons mis en lumière la voie de signalisation associée aux effets immunosuppresseurs de NLRP3 dans les T CD4 et les T CD8.De telles découvertes fondamentales pourraient être utilisées pour développer des outils ciblant les cellules T. Grâce à mes travaux, nous pensons que NLRP3 régule l'activation et/ou la différenciation des lymphocytes T CD4 et des T CD8 chez la souris, permettant l'identification de nouvelles cibles thérapeutiques pour éviter ou inverser l'immunosuppression associée à NLRP3.
- Open Access
- 7 April 2025
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 22 (5) , 541-556
The intrinsic expression of NLRP3 in Th17 cells promotes their protumor activity and conversion into Tregs
: Th17 cells can perform either regulatory or inflammatory functions depending on the cytokine microenvironment. These plastic cells can transdifferentiate into Tregs during inflammation resolution, in allogenic heart transplantation models, or in cancer through mechanisms that remain poorly understood. Here, we demonstrated that NLRP3 expression in Th17 cells is essential for maintaining their immunosuppressive functions through an inflammasome-independent mechanism. In the absence of NLRP3, Th17 cells produce more inflammatory cytokines (IFNγ, Granzyme B, TNFα) and exhibit reduced immunosuppressive activity toward CD8+ cells. Moreover, the capacity of NLRP3-deficient Th17 cells to transdifferentiate into Treg-like cells is lost. Mechanistically, NLRP3 in Th17 cells interacts with the TGF-β receptor, enabling SMAD3 phosphorylation and thereby facilitating the acquisition of immunosuppressive functions. Consequently, the absence of NLRP3 expression in Th17 cells from tumor-bearing mice enhances CD8 + T-cell effectiveness, ultimately inhibiting tumor growth.
- 7 April 2025
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 22 (5) , 541-556
Open AccessThe intrinsic expression of NLRP3 in Th17 cells promotes their protumor activity and conversion into Tregs
: Th17 cells can perform either regulatory or inflammatory functions depending on the cytokine microenvironment. These plastic cells can transdifferentiate into Tregs during inflammation resolution, in allogenic heart transplantation models, or in cancer through mechanisms that remain poorly understood. Here, we demonstrated that NLRP3 expression in Th17 cells is essential for maintaining their immunosuppressive functions through an inflammasome-independent mechanism. In the absence of NLRP3, Th17 cells produce more inflammatory cytokines (IFNγ, Granzyme B, TNFα) and exhibit reduced immunosuppressive activity toward CD8+ cells. Moreover, the capacity of NLRP3-deficient Th17 cells to transdifferentiate into Treg-like cells is lost. Mechanistically, NLRP3 in Th17 cells interacts with the TGF-β receptor, enabling SMAD3 phosphorylation and thereby facilitating the acquisition of immunosuppressive functions. Consequently, the absence of NLRP3 expression in Th17 cells from tumor-bearing mice enhances CD8 + T-cell effectiveness, ultimately inhibiting tumor growth.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
Supplementary Figure from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
Supplementary Figure from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- Open Access
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- 4 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- 25 May 2022
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (7) , 900-916
Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- 25 May 2022
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (7) , 900-916
Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects
T follicular helper (Tfh) cells are a subset of CD4+ T cells essential in immunity and have a role in helping B cells produce antibodies against pathogens. However, their role during cancer progression remains unknown. The mechanism of action of Tfh cells remains elusive because contradictory data have been reported on their protumor or antitumor responses in human and murine tumors. Like Tfh cells, Th2 cells are also involved in humoral immunity and are regularly associated with tumor progression and poor prognosis, mainly through their secretion of IL4. Here, we showed that Tfh cells expressed hematopoietic prostaglandin D2 (PGD2) synthase in a pSTAT1/pSTAT3-dependent manner. Tfh cells produced PGD2, which led to recruitment of Th2 cells via the PGD2 receptor chemoattractant receptor homologous molecule expressed on Th type 2 cells (CRTH2) and increased their effector functions. This cross-talk between Tfh and Th2 cells promoted IL4-dependent tumor growth. Correlation between Th2 cells, Tfh cells, and hematopoietic PGD2 synthase was observed in different human cancers and associated with outcome. This study provides evidence that Tfh/Th2 cross-talk through PGD2 limits the antitumor effects of Tfh cells and, therefore, could serve as a therapeutic target.
- Open Access
- 8 June 2021
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 9 (6) , e002157
Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
Background: T follicular helper cells (Tfh) are essential to shape B cell response during germinal center formation. Tfh accumulation has been reported in various human cancers, with positive or negative prognostic roles. However, the mechanisms explaining the accumulation of Tfh and their role in cancer remain obscure. Methods: In vitro differentiated and mouse cell sorted Tfh phenotype was evaluated by flow cytometry and quantitative PCR (qPCR). Antitumor effect of Tfh was evaluated by adoptive transfer in different tumor-bearing mice models. The involvement of immune cells, cytokines and chemokines was evaluated, using depleting antibodies. Chemokines and cytokines expression and production were evaluated by qPCR and ELISA. In human, the impact of immune cells and chemokines on survival was evaluated by analyzing transcriptomic data from public databases and from our own patient cohorts. Results: In this study, we show that Tfh exert an antitumor immune effect in a CD8+-dependent manner. Tfh produce interleukin-21, which sustains proliferation, viability, cytokine production and cytotoxic functions of exhausted T cells. The presence of Tfh is required for efficacy of antiprogrammed cell death ligand-1 therapy. Tfh accumulate in the tumor bed and draining lymph nodes in different mouse cancer models. This recruitment is due to the capacity of transforming growth factor β to drive Chemokine (C-X-C motif) Ligand 13 expression, a chemoattractant of Tfh, by intratumor CD8+ T cells. Accumulation of Tfh and exhausted CD8+ T cells predicts cancer outcome in various cancer types. In patients treated with anti-programmed cell death-1 mAb, accumulation of Tfh and CD8+ at the tumor site is associated with outcome. Conclusion: This study provides evidence that CD8+/Tfh crosstalk is important in shaping antitumor immune response generated by immunotherapy.
- 8 June 2021
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 9 (6) , e002157
Open AccessFollicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
Background: T follicular helper cells (Tfh) are essential to shape B cell response during germinal center formation. Tfh accumulation has been reported in various human cancers, with positive or negative prognostic roles. However, the mechanisms explaining the accumulation of Tfh and their role in cancer remain obscure. Methods: In vitro differentiated and mouse cell sorted Tfh phenotype was evaluated by flow cytometry and quantitative PCR (qPCR). Antitumor effect of Tfh was evaluated by adoptive transfer in different tumor-bearing mice models. The involvement of immune cells, cytokines and chemokines was evaluated, using depleting antibodies. Chemokines and cytokines expression and production were evaluated by qPCR and ELISA. In human, the impact of immune cells and chemokines on survival was evaluated by analyzing transcriptomic data from public databases and from our own patient cohorts. Results: In this study, we show that Tfh exert an antitumor immune effect in a CD8+-dependent manner. Tfh produce interleukin-21, which sustains proliferation, viability, cytokine production and cytotoxic functions of exhausted T cells. The presence of Tfh is required for efficacy of antiprogrammed cell death ligand-1 therapy. Tfh accumulate in the tumor bed and draining lymph nodes in different mouse cancer models. This recruitment is due to the capacity of transforming growth factor β to drive Chemokine (C-X-C motif) Ligand 13 expression, a chemoattractant of Tfh, by intratumor CD8+ T cells. Accumulation of Tfh and exhausted CD8+ T cells predicts cancer outcome in various cancer types. In patients treated with anti-programmed cell death-1 mAb, accumulation of Tfh and CD8+ at the tumor site is associated with outcome. Conclusion: This study provides evidence that CD8+/Tfh crosstalk is important in shaping antitumor immune response generated by immunotherapy.
- Open Access
- 1 March 2021
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 9 (3) , 324-336
The Tumor Microenvironment Impairs Th1 IFNγ Secretion through Alternative Splicing Modifications of Irf1 Pre-mRNA
It is clearly established that the immune system can affect cancer response to therapy. However, the influence of the tumor microenvironment (TME) on immune cells is not completely understood. In this respect, alternative splicing is increasingly described to affect the immune system. Here, we showed that the TME, via a TGFβ-dependent mechanism, increased alternative splicing events and induced the expression of an alternative isoform of the IRF1 transcription factor (IRF1Δ7) in Th1 cells. We found that the SFPQ splicing factor (splicing factor, proline- and glutamine-rich) was responsible for the IRF1Δ7 production. We also showed, in both mice and humans, that the IRF1 alternative isoform altered the full-length IRF1 transcriptional activity on the Il12rb1 promoter, resulting in decreased IFNγ secretion in Th1 cells. Thus, the IRF1Δ7 isoform was increased in the TME, and inhibiting IRF1Δ7 expression could potentiate Th1 antitumor responses.
- 1 March 2021
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 9 (3) , 324-336
Open AccessThe Tumor Microenvironment Impairs Th1 IFNγ Secretion through Alternative Splicing Modifications of Irf1 Pre-mRNA
It is clearly established that the immune system can affect cancer response to therapy. However, the influence of the tumor microenvironment (TME) on immune cells is not completely understood. In this respect, alternative splicing is increasingly described to affect the immune system. Here, we showed that the TME, via a TGFβ-dependent mechanism, increased alternative splicing events and induced the expression of an alternative isoform of the IRF1 transcription factor (IRF1Δ7) in Th1 cells. We found that the SFPQ splicing factor (splicing factor, proline- and glutamine-rich) was responsible for the IRF1Δ7 production. We also showed, in both mice and humans, that the IRF1 alternative isoform altered the full-length IRF1 transcriptional activity on the Il12rb1 promoter, resulting in decreased IFNγ secretion in Th1 cells. Thus, the IRF1Δ7 isoform was increased in the TME, and inhibiting IRF1Δ7 expression could potentiate Th1 antitumor responses.